SYVN1 and laryngotracheoesophageal cleft: We further tested the prognostic potential of ABHD17A, PSME4, CSNK1D, and SYVN1, which had showed diagnostic ability between LC and NLC groups, and the result showed that ABHD17A had a 3.68-fold increase in the 12-month Non-Relief cohort (Fig. 3c).